Trial of Radiotherapy for Lung Metastases in Soft Tissue Sarcoma
Researchers are evaluating stereotactic body radiation therapy with adaptive radiation therapy for the treatment of non-resectable lung metastases from a primary soft tissue sarcoma.
Title: Pilot Study Evaluating Stereotactic Body Radiation Therapy (SBRT) and Adaptive Radiation Therapy (ART) for Pulmonary Metastases From Soft Tissue Sarcomas1
Principal Investigators: Manpreet Bedi, MD, Medical College of Wisconsin
Description: For this non-randomized, single arm study, researchers are evaluating stereotactic body radiation therapy (SBRT) with adaptive radiation therapy (ART) for the treatment of non-resectable lung metastases from a primary soft tissue sarcoma.
Patients must be 18 years or older with 1 to 5 lung metastases; no metastasis can be larger than 5 cm.
SBRT with ART will be used for all patients; each metastasis will receive 3 to 5 fractions; 1 to 3 treatments will be conducted per week until completion. Follow-up will occur for 3 years.
The primary outcome is safety and toxicity; secondary outcomes include local/regional control, quality of life, and overall survival.
For more study information, including inclusion and exclusion criteria, study locations, and contact information, visit https://clinicaltrials.gov/ct2/show/NCT01949506.
Status: This study is open and recruiting participants as of April 17, 2017.
This study is sponsored by the Medical College of Wisconsin.
- Clinicaltrials.gov. (SBRT) and (ART) for pulmonary metastases from soft tissue sarcomas. NCT01949506. https://clinicaltrials.gov/ct2/show/NCT01949506. Accessed April 17, 2017.